Eli Lilly and Co

Novo Nordisk's stock dropped 18% after its obesity drug CagriSema, in a late-stage trial, showed average weight loss of 22.7%, missing the 25% goal. This result was only slightly better than Eli Lilly's Zepbound, which saw a 20.2% weight loss. Karen Andersen, Morningstar's director of equity research, healthcare, expects the balance of power in obesity treatments to shift between Novo and Lilly based on future data releases.

FDA approves Zepbound® (tirzepatide) for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity, the first prescription medicine for this condition. Zepbound, used with a reduced-calorie diet and increased physical activity, showed significant improvements in OSA symptoms and weight loss in clinical trials.

Sorriso Pharmaceuticals' Phase Ib trial of SOR102, an oral drug for ulcerative colitis, met its endpoints, showing safety, tolerability, and significant clinical improvements. The company plans to advance to Phase II trials in 2025.

FDA expands Eli Lilly's Zepbound approval for treating moderate to severe obstructive sleep apnea in obese individuals, marking the first medication for the condition. The approval may lead to insurance coverage, including Medicare, for those with both sleep apnea and obesity. Zepbound users experienced reduced breathing interruptions and weight loss, with up to half no longer showing symptoms after a year.

FDA approves Zepbound (tirzepatide) as the first prescription medication for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Clinical trials showed Zepbound reduced breathing interruptions by 25-29 events per hour and promoted substantial weight loss, with up to 50% experiencing remission or mild OSA symptoms after one year.

The FDA approved tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea and obesity, based on the SURMOUNT-OSA trial. Tirzepatide met primary and secondary endpoints, reducing Apnea-Hypopnea Index and improving hypoxic burden. It's the first drug treatment for certain patients with obstructive sleep apnea, to be used with a reduced-calorie diet and increased physical activity.

FDA approves Zepbound for moderate to severe OSA and obesity, showing significant efficacy and weight loss in clinical trials.

Zepbound (tirzepatide), a weight-loss drug, is now the first FDA-approved treatment for obstructive sleep apnea. Trials showed it reduced breathing interruptions by 63%, leading to 30 fewer events nightly. The drug helps maintain open airways by reducing fat tissue, benefiting those with obesity and sleep apnea.

The FDA approved Zepbound, a weight-loss drug, for treating moderate to severe obstructive sleep apnea in obese individuals. It should be used with a reduced-calorie diet and increased physical activity. Clinical trials showed significant improvements in sleep apnea symptoms and weight loss, with common side effects being mild to moderate gastrointestinal events.

Novo Nordisk's stock dropped 21% after its obesity drug CagriSema showed less weight loss than expected, averaging 22.7%. Competitor Eli Lilly's stock rose 5%.